Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

Addgene
Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironment.
Hariharan A, Qi W, Rehrauer H, Wu L, Ronner M, Wipplinger M, Kresoja-Rakic J, Sun S, Oton-Gonzalez L, Sculco M, Serre-Beinier V, Meiller C, Blanquart C, Fonteneau JF, Vrugt B, Ruschoff JH, Opitz I, Jean D, de Perrot M, Felley-Bosco E
Mol Oncol. 2022 Dec;16(22):3949-3974. doi: 10.1002/1878-0261.13322. Epub 2022 Oct 31.
PubMed Article

Plasmids from Article

ID Plasmid Purpose
158112pSpCas9_human_ADAR2_ccCdeletion hADAR2
158113pSpCas9_human_ADAR2_ccBdeletion hADAR2
158114pSpCas9_human_ADAR2_ccAdeletion hADAR2
158117pSpCas9_mouse_Adar2_ccCdeletion mADAR2
158118pSpCas9_mouse_Adar2_ccAdeletion mADAR2
158119pSpCas9_mouse_Adar2_ccBdeletion mADAR2
175588BII-ChBtW-mADAR2-shortmammalian expression of mouse short Adar2, blasticidine selection

Antibodies from Article